Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov
Condition: Breast Cancer
Study Type: Interventional
Phase: Phase II
Study Start Date: 06/04/2015
Study Completion Date: 12/30/2018
This multicenter, randomized, double-blind study will evaluate the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC). The safety of single-agent nab-paclitaxel has been determined in previous studies of participants with mBC and the safety data to date suggest that atezolizumab can be safely combined with standard chemotherapy agents.